Category: Side Effect: Neurological (intracranial meningioma, progressive multifocal leukoencephalopathy)
-
What The Depo-Provera Meningioma Warning Added In 2025 Means For New Depo-Provera Lawsuits In 2026
Women Who Had Depo-Provera Injections Before December 2025 Label Change Can Still Sue Responsible Pharmaceutical Drug Companies (Posted by Tom Lamb at Drug Injury Watch) In December 2025, a Depo-Provera “meningioma warning” label change was required by…
-
Depo-Provera Meningioma Cases: Women With At Least 4 Years Use or Starting Injections After Age 31
Higher Risk Of Meningioma Side Effects Associated With Depo-Provera for These Women, According to a 2025 Medical Study Report (Posted by Tom Lamb at Drug Injury Watch) A recent medical study looking at Depo-Provera meningioma cases in…
-
Depo-Provera Drug Label Warnings in US Do Not Include Increased Risk of Intracranial Meningioma
While European Union (EU) and United Kingdom (UK) Drug Labels Have Warned About Meningioma for Many Years (Posted by Tom Lamb at Drug Injury Watch) Drug injury lawsuits that involve the contraceptive injection Depo-Provera being linked to…
-
Side Effects of Birth Control: Brain Tumors Related to Depo-Provera Contraceptive Injections
Intracranial Meningioma Risks Are Increased When Depo-Provera Was Used for More Than One Year (Posted by Tom Lamb at Drug Injury Watch) See also: “Depo-Provera Drug Label Warnings in US Do Not Include Increased Risk of Intracranial…
-
Xeljanz: Drug-induced Peripheral Neuropathy as Possible Xeljanz Side Effect in 2 RA Patients
Reports of Rheumatoid Arthritis Patients on Xeljanz Experiencing Secondary Neurological Adverse Events (Posted by Tom Lamb at Drug Injury Watch) As we have written about previously, according to the FDA, some of the generally recognized…
-
First Monotherapy Ocrevus PML Case Report: Patient Used Ocrevus for 2 Years Without Prior Immunotherapy
Compare 9 Earlier Cases of PML in MS Patients After Ocrevus Treatments: Those Involved Previous Tysabri and/or Gilenya Use (Posted by Tom Lamb at Drug Injury Watch) Pharmaceutical company Genentech knew about the first monotherapy…
-
European Drug Regulator EMA Suspends Use Of MRI Drugs Magnevist, Omniscan, And OptiMARK In July 2017
The Drug Safety Concern Is That Use Of These Gadolinium Contrast Agents Can Leave Gadolinium Deposits In Brain Tissues (Posted by Tom Lamb at DrugInjuryWatch.com) The European Medicines Agency (EMA) recently announced…
-
New MS Drug Ocrevus Gets Possible Bad News About Side Effects Soon After Good News About Sales Projections
Ocrevus – Progressive Multifocal Leukoencephalopathy (PML) Reported As Possible Side Effect In Germany, Says Drug Maker Roche (Posted by Tom Lamb at DrugInjuryWatch.com) In March 2017 the FDA approved Ocrevus (ocrelizumab injection)…
-
Multiple Sclerosis Drug Tecfidera: FDA Mandates January 2017 Label Change Which Adds Warnings About Liver Injury Cases
Besides Hepatotoxicity, Progressive Multifocal Leukoencephalopathy, Renal Toxicity, And Other Safety Issues Have Surfaced Since Clinical Trials (Posted by Tom Lamb at DrugInjuryWatch.com) Tecfidera (dimethyl fumarate) was approved by the FDA in 2013…
-
A Tecfidera Label Change Modifying Warnings About Progressive Multifocal Leukoencephalopathy (PML) Was Done In February 2016 With Little Notice
Biogen Idec First Added Information About Tecfidera Being Assoicated With PML Brain Infection Back In December 2014, After An FDA Drug Safety Communication Was Issued (Posted by Tom Lamb at DrugInjuryWatch.com) Tecfidera…